Description: <p><b>Lambertianic acid</b> — a naturally occurring labdane-type diterpenoid carboxylic acid found in several conifer species, particularly <i>Pinus koraiensis</i>, <i>Pinus lambertiana</i>, and <i>Platycladus orientalis</i>. It is an experimental natural-product small molecule rather than an approved drug. The abbreviation <b>LA</b> is commonly used in the scientific literature, although the Nestronics product abbreviation is <b>lamb</b>. Lambertianic acid has reported anticancer, anti-inflammatory, anti-allergic, metabolic, and muscle-protective activities, but its therapeutic evidence remains predominantly cellular and preclinical. Its anticancer activity appears strongly context-dependent and involves coordinated effects on oxidative stress, AMPK signaling, cancer metabolism, STAT3/NF-κB survival signaling, androgen receptor signaling, and apoptosis.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>↑ ROS with ROS-dependent activation of LKB1/AMPK/ACC signaling, producing metabolic stress and apoptosis in susceptible cancer cells.</li>
<li>↓ PKM2/HK2/LDHA-driven glycolysis and ↓ PKM2/β-catenin signaling, producing an anti-Warburg metabolic effect.</li>
<li>↓ STAT3 and NF-κB signaling, including ↓ STAT3 phosphorylation, ↓ RelA/p65 activation/acetylation, and suppression of downstream survival and inflammatory proteins.</li>
<li>↑ intrinsic and extrinsic apoptosis through caspase activation, PARP cleavage, ↓ BCL-2/BCL-xL/XIAP/survivin, and context-dependent ↑ DR4/TRAIL sensitivity.</li>
<li>↑ AMPK with ↓ AKT/mTOR and ↓ FOXM1 signaling, contributing to growth arrest and apoptosis.</li>
<li>↓ androgen receptor signaling in androgen-responsive prostate cancer, with ↓ AR nuclear signaling and ↓ PSA.</li>
<li>Cell-cycle inhibition through ↓ cyclin D1/CDK4/CDK6 or ↓ cyclin B1 and context-dependent ↑ p53/p21/p27.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Human pharmacokinetic parameters, oral bioavailability, plasma half-life, distribution, metabolism, and clinically achievable concentrations have not been adequately established. Lambertianic acid is a lipophilic diterpenoid and should therefore not be assumed to achieve the micromolar exposures used in cell-culture studies after ordinary dietary or oral exposure. No validated therapeutic dosing regimen exists.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer experiments use approximately 10–200 µM lambertianic acid, depending on the model. Some signaling effects occur around 15–30 µM, whereas androgen-receptor prostate-cancer experiments used substantially higher concentrations, including approximately 100–200 µM. There is currently insufficient human PK evidence to demonstrate that these concentrations are systemically achievable. Normal-cell selectivity is also incompletely characterized; recent C2C12 studies found little cytotoxicity at 12.5–25 µM but measurable loss of viability at 50–100 µM.</p>
<p><b>Clinical evidence status:</b> <b>Preclinical.</b> Evidence consists primarily of cultured cancer cells with limited animal-supporting evidence from non-cancer metabolic studies. No established randomized clinical trial evidence, approved oncologic indication, validated human anticancer dose, or regulatory approval for lambertianic acid as a therapeutic agent was identified.</p>
<h3>Lambertianic Acid Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ROS-LKB1-AMPK-ACC metabolic stress</td>
<td>ROS ↑; LKB1 ↑; AMPK ↑; ACC phosphorylation ↑</td>
<td>Not established</td>
<td>G</td>
<td>Apoptosis and metabolic stress ↑</td>
<td>ROS scavenging with NAC substantially reverses several anticancer effects, supporting ROS as a mechanistically important upstream event rather than merely a secondary marker.</td>
</tr>
<tr>
<td>2</td>
<td>Glycolysis and PKM2-beta-catenin axis</td>
<td>PKM2 ↓; p-PKM2 ↓; HK2 ↓; LDHA ↓; lactate production ↓; beta-catenin ↓; glycolysis ↓</td>
<td>Not established</td>
<td>G</td>
<td>Warburg metabolism ↓; apoptosis ↑</td>
<td>Particularly demonstrated in DU145 and PC3 prostate cancer cells. ROS contributes upstream to suppression of PKM2 and associated metabolic signaling.</td>
</tr>
<tr>
<td>3</td>
<td>STAT3-NF-kB-p300-RelA survival signaling</td>
<td>p-STAT3 ↓; NF-kB activation ↓; p300 ↓; RelA acetylation ↓; nuclear translocation ↓</td>
<td>Not established</td>
<td>G</td>
<td>Survival and inflammatory signaling ↓</td>
<td>Associated with ↓ XIAP, survivin, BCL-2, BCL-xL, VEGF, COX-2, c-Myc, IL-6 and TNF-alpha. miR-134 ↑ appears to participate in this pathway.</td>
</tr>
<tr>
<td>4</td>
<td>Intrinsic apoptosis</td>
<td>Caspase-3 ↑; caspase-9 ↑; PARP cleavage ↑; BAX ↑; BCL-2 ↓</td>
<td>Not adequately established</td>
<td>G</td>
<td>Apoptosis ↑</td>
<td>Observed across prostate, hepatocellular, breast and lung cancer models. Apoptotic response is frequently downstream of AMPK activation and suppression of survival signaling.</td>
</tr>
<tr>
<td>5</td>
<td>AMPK-AKT-mTOR-FOXM1 axis</td>
<td>AMPK ↑; AKT ↓; mTOR ↓; FOXM1 ↓; cyclin B1 ↓</td>
<td>AMPK modulation reported in non-cancer metabolic models</td>
<td>G</td>
<td>Proliferation ↓; apoptosis ↑</td>
<td>AMPK inhibition reverses several lambertianic-acid effects, supporting a functional rather than merely correlative role for AMPK.</td>
</tr>
<tr>
<td>6</td>
<td>Androgen receptor signaling</td>
<td>AR ↓; AR nuclear translocation ↓; PSA ↓</td>
<td>Not established</td>
<td>G</td>
<td>Androgen-dependent proliferation ↓</td>
<td>Best demonstrated in LNCaP prostate cancer cells. Relatively high concentrations were required compared with several later mechanistic studies.</td>
</tr>
<tr>
<td>7</td>
<td>Cell-cycle regulation</td>
<td>Cyclin D1 ↓; CDK4 ↓; CDK6 ↓; p53 ↑; p21 ↑; p27 ↑; cyclin B1 ↓</td>
<td>Not established</td>
<td>G</td>
<td>G1 or G2/M arrest ↑ (model-dependent)</td>
<td>Cell-cycle phenotype varies by cancer model. LNCaP cells predominantly demonstrate G1 arrest, whereas breast-cancer studies report G2/M-associated effects.</td>
</tr>
<tr>
<td>8</td>
<td>TRAIL death-receptor sensitization</td>
<td>DR4 ↑; caspase-8 ↑; Bid activation ↑; XIAP ↓; FLIP ↓; NF-kB ↓</td>
<td>Not established</td>
<td>G</td>
<td>TRAIL-induced apoptosis ↑</td>
<td>Lambertianic acid sensitized A549 and H1299 non-small-cell lung cancer cells to TRAIL. This is a combination-dependent chemosensitization-like mechanism rather than evidence of clinical combination efficacy.</td>
</tr>
<tr>
<td>9</td>
<td>Angiogenic and inflammatory survival factors</td>
<td>VEGF ↓; COX-2 ↓; IL-6 ↓; TNF-alpha ↓</td>
<td>COX-2, IL-6, PGD2 and LTC4 ↓ in activated mast-cell models</td>
<td>G</td>
<td>Inflammatory and pro-survival signaling ↓</td>
<td>These effects overlap substantially with suppression of STAT3 and NF-kB and are therefore best considered downstream or secondary mechanisms.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Effective concentrations commonly in micromolar range</td>
<td>Normal-cell therapeutic window incompletely defined</td>
<td>G</td>
<td>Clinical applicability uncertain</td>
<td>Human PK, oral bioavailability, dose-limiting toxicity, target exposure, long-term safety and anticancer efficacy have not been established. Current evidence does not justify assuming that experimental concentrations are achievable in humans.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>